INO has been in the news 500% more than usual
Feb 23, 2026, 9:31 AM
-9.51%
What does INO do
Inovio Pharmaceuticals, based in San Diego, develops DNA medicines targeting infectious diseases, cancer, and HPV-related conditions, with key candidates including INO-3107 for recurrent respiratory papillomatosis. The company employs 122 people and utilizes CELLECTRA devices for DNA delivery.
INO has been in the news recently: Rosen Law Firm and DJS Law Group have announced class actions against Inovio Pharmaceuticals, alleging the company made false statements about its CELLECTRA device and INO-3107 that harmed investors. Both firms say investors who bought Inovio shares between October 10, 2023 and December 26, 2025 may be eligible to join, with an April 7, 2026 filing deadline.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.